Publications by authors named "N Moriwaki"
Article Synopsis
- Vancomycin regimens aim for an AUC/MIC ratio of 400-600 µg·h/mL, but early treatment for severe infections may depend on the first 24-hour AUC/MIC measurements.
- This study analyzed MRSA bacteremia cases to see how the first 24-hour AUC/MIC impacted treatment outcomes, using a cutoff of 300 µg·h/mL to categorize patients.
- Results showed no significant difference in treatment efficacy or 30-day survival between groups, but those with an AUC/MIC < 300 had a longer time to clinical and bacteriological improvement, suggesting that while early AUC/MIC levels do not change success rates, they may influence recovery times.
Photomutagenicity of N-nitrosoproline dissolved in non-aqueous solvent, oleic acid.
Mutat Res Genet Toxicol Environ Mutagen
August 2024
In the present study, we investigated the genotoxicity of the active products formed from N-nitrosoproline (NPRO) dissolved in oleic acid following ultraviolet A (UVA) irradiation, bypassing the need for metabolic activation. We previously demonstrated the photomutagenicity of NPRO dissolved in a phosphate-buffered solution. It has been suggested that the association of the nitrosamine group with acid ions facilitates rapid photodissociation and photoactivation.
View Article and Find Full Text PDF: Remdesivir (RDV) is the first antiviral agent approved in Japan for the treatment of coronavirus disease 2019 (COVID-19). The aim of our study was to assess the efficacy and safety of RDV treatment in mildly to moderately ill patients with COVID-19. A single-center, retrospective study was performed in Fukuoka University Chikushi Hospital.
View Article and Find Full Text PDFObjective: The objective of this study was to evaluate the effects of earlier intervention by an antimicrobial stewardship team (AST) on antimicrobial use, antimicrobial resistance rates, and the clinical outcomes, without changing the weekly intervention schedule.
Methods: A retrospective study was conducted at Fukuoka University Hospital between April 2013 and March 2016. The effects were compared among three study periods (SP): SP1 (patients receiving anti-methicillin-resistant Staphylococcus aureus agents and carbapenems for ≥14 days), SP2 (patients receiving specific antimicrobials for ≥14 days), and SP3 (patients receiving specific antimicrobials regardless of the duration of treatment).
Quercetin 3-O-β-monoglucopyranoside and quercetin 3-O-β-maltooligosaccharide were synthesized from quercetin using glucosyltransferase-3 from Phytolacca americana and cyclodextrin glucanotransferase.
View Article and Find Full Text PDF